Sagimet Biosciences Inc. Class A (SGMT)

Over the past six months, Sagimet Biosciences' stock has been influenced by several events. These include insider selling in November 2025, participation in healthcare conferences, and the release of Fourth Quarter and Full Year 2025 financial results in March 2026. In April 2026, Andreas Grauer was appointed as the new Chief Medical Officer, and the company announced plans for a U.S. Phase 3 clinical trial of oral denifanstat for moderate to severe acne. Sagimet also announced the pricing of a $175.0 million underwritten offering of Series A Common Stock. As of May 2026, the stock price was $7.64, with analysts maintaining a "Moderate Buy" consensus rating.

As a clinical-stage biopharmaceutical company, Sagimet Biosciences' revenue is primarily tied to research and development milestones, potential licensing agreements, and eventual commercialization of its drug candidates. There is no discernible demand seasonality for Sagimet Biosciences' products or services in the traditional sense.

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics, particularly fatty acid synthase (FASN) inhibitors. Their lead product candidate, denifanstat, is in development for MASH and acne, with positive trial results. The company is also exploring its use in cancer. Other product candidates include TVB-3567 and FASNi Topical.

Sagimet Biosciences is headquartered in San Mateo, California, and primarily focuses on developing therapeutics for diseases in the United States. They have a licensing agreement with Ascletis BioScience Co. Ltd. for denifanstat in Greater China for acne and recurrent glioblastoma multiforme.

Sagimet Biosciences has maintained a generally positive brand reputation over the past year, driven by clinical development progress and positive analyst sentiment. Key events include positive topline results from clinical trials, FDA Breakthrough Therapy designation, and analyst coverage reflecting a "Moderate Buy" consensus rating. The company's strategic decisions and financial stability have further supported its reputation.

Sagimet Biosciences Inc. has a diverse ownership structure, including institutional owners, individual investors, and individual insiders. As of May 8, 2026, there are 87 institutional owners holding a total of 14,452,987 shares. Individual investors held 32% ownership as of March 14, 2024. Insider sentiment is considered neutral, with some insider selling activity in February 2026.